Cencora, Inc. (NYSE:COR) experienced a notable increase in its stock price, rising by 9.1% during trading on Thursday after the company announced stronger-than-expected earnings. The stock peaked at $359.10 before settling at $359.90 by the end of the trading day. Approximately 383,655 shares changed hands, representing a significant drop of 68% from the average daily volume of 1,195,642 shares. The previous closing price stood at $329.97.
The company reported an earnings per share (EPS) of $4.08 for the quarter, exceeding analysts’ consensus estimates of $4.04 by $0.04. Cencora’s net margin was recorded at 0.48%, with a remarkable return on equity of 227.15%. The total revenue for the quarter was $85.93 billion, slightly below the analysts’ expectations of $86.12 billion. This figure reflects a year-over-year revenue increase of 5.5%, compared to the same period last year when the company reported an EPS of $3.73.
Dividend Announcement and Strategic Developments
In addition to the earnings report, Cencora announced a quarterly dividend of $0.60 per share, which is set to be paid on March 2, 2024. Shareholders on record as of February 13, 2024, will receive this dividend, which translates to an annualized amount of $2.40 and a dividend yield of 0.7%. The company’s current dividend payout ratio stands at 30.19%.
Cencora’s management has expressed positive sentiment regarding its earnings and operational outlook. The firm raised its fiscal 2026 operating income growth targets to between 11.5% and 13.5%. This optimistic revision comes as the company integrates its recent acquisition of OneOncology, a move that management believes will enhance specialty oncology volume and foster further revenue and margin expansion.
Analysts have responded positively to the earnings report, with several rating revisions. Mizuho raised its price target on Cencora from $340.00 to $380.00, maintaining an “outperform” rating. Jefferies Financial Group upgraded their rating from “underperform” to “buy,” while Barclays initiated coverage with an “overweight” rating and a price target of $400.00.
Market Reactions and Insider Activity
Despite the encouraging earnings announcement, the stock faced some pressure due to a slight revenue miss compared to expectations, which triggered intra-day selling. Market reactions indicated a focus on near-term revenue execution. The stock underperformed compared to peers, suggesting a market preference for companies demonstrating strong top-line growth.
In recent insider activity, Executive Vice President Silvana Battaglia sold 1,677 shares at an average price of $345.00, totaling approximately $578,565. Following this transaction, she retains ownership of 18,796 shares valued at about $6.48 million. CEO Robert P. Mauch also sold 5,096 shares for a total of $1.87 million, reducing his ownership by 7.19%.
Institutional investors have shown active engagement with Cencora’s stock. Atlantic Edge Private Wealth Management LLC increased its holdings by 70% in the second quarter, while Oakworth Capital Inc. and Archer Investment Corp. acquired new stakes or increased existing ones. Currently, 97.52% of Cencora’s stock is owned by hedge funds and institutional investors.
Cencora operates as a global healthcare services and pharmaceutical distribution company, providing comprehensive solutions across the pharmaceutical supply chain. Its core activities include wholesale drug distribution, specialty drug distribution, and specialty pharmacy operations, supported by logistics and fulfillment services.
As Cencora continues to integrate its recent acquisition and implement its growth strategy, market observers will be keenly watching its performance in the upcoming quarters to gauge the effectiveness of its business model and strategic initiatives.
